Persuading natural killer cells to eliminate bad B cells

Clinical Cancer Research

Volumn 15, Issue 15, 2009, Pages 4790-4791

  Cooper, Laurence J N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

B CELL LEUKEMIA; B LYMPHOCYTE; DNA MODIFICATION; HUMAN; NATURAL KILLER CELL; NOTE; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ANTIGENS, CD19; B-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 68049128101     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0966     Document Type: Note

References (12)

1. Altvater B, Landmeier S, Pscherer S, et al. 2B4 (CD244)signa ling by recombinant antigenspecific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res 2009;15: 4857-4866
2. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100 (Pubitemid 34229476)
3. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433-440 (Pubitemid 47026866)
4. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-3057 (Pubitemid 40504320)
5. Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008;68:2961-2971 (Pubitemid 351556297)
6. Eshhar Z, Bach N, Fitzer-Attas CJ, et al. The T-body approach: potential for cancer immunotherapy. Springer Semin Immunopathol 1996;18:199-209. (Pubitemid 26335406)
7. Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21:215-223
8. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006;66: 10995-11004 (Pubitemid 44876999)
9. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106: 376-383 (Pubitemid 40967217)
10. Baron F, Petersdorf EW, Gooley T, et al. What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant 2009;15:580-588
11. Diermayr S, Himmelreich H, Durovic B, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008;111:1428-1436 (Pubitemid 351213430)
12. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009. Epub 2009 Apr 21.